Work

Assessment of Out-of-Pocket Costs With Rebate Pass-through for Brand-name Cancer Drugs Under Medicare Part D

Year: 2021

Type: article

Abstract: This cross-sectional study examines patients’ out-of-pocket costs with and without rebate pass-through to point-of-sale prices for cancer drugs under Medicare Part D.

Source: JAMA Oncology

DOI: 10.1001/jamaoncol.2021.5433

Authors: Thomas J. Hwang, Xuanzi Qin, Nancy L. Keating, Haiden A. Huskamp, Stacie B. Dusetzina

Institutions: Brigham and Women's Hospital, Harvard University, Vanderbilt University Medical Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center

Language: English

Topic: Economic and Financial Impacts of Cancer

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W3213084116

FWCI: 1.7

Cites: 1

Cited by: 13

Related to: 10